LAUSR

CSVV: cutaneous small vessel vasculitis INTRODUCTION Two single-dose COVID-19 vaccines utilizing the adenoviral vector platform, ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen), have recently been associated with rare immune-mediated thrombotic events and thrombocytopenia. In response to 6 reports on Ad26.COV2.S-associated thrombosis, the US Food and Drug Administration recommended a brief pause in the use of the Ad26.COV2.S vaccine on April 13, 2021. After further investigation, the US Food and Drug Administration and Centers for Disease Control and Prevention concluded that the vaccine’s benefits outweigh the low riskof thrombosis and recommended the resumption of Ad26.COV2.S vaccination with a manufacturer warning for possible thrombosis. Although available evidence clearly demonstrates that both vaccines are efficacious and otherwise safe, further characterization of any vaccine-associated adverse events is necessary for public health and future vaccine development. We report a case of cutaneous small vessel vasculitis (CSVV) in a SARS-CoV-2 patient 1 week after inoculation with Ad26.COV2.S that rapidly resolved following treatment with systemic and topical corticosteroids.